I’m looking to top up my Stocks and Shares ISA before April’s deadline, and the following FTSE 100 stocks have all caught my eye. They’re the type of companies investors overlook, so there’s not much froth in their valuations. I’m a longstanding fan of unsung hero Bunzl (LSE: BNZL). This £11bn outsourcing ...
motleyfooluklse:gsklse:bnzllse:sdr
GSK’s (LSE: GSK) share price is around an 18-month high. But just because a stock has risen a lot does not automatically mean that it is overvalued. It could simply be that the company is worth more than it was before. In fact, it could well be worth even more than the current share price reflects. Undervalued ...
motleyfooluklse:gsk
Premium content from Motley Fool Share Advisor UK Our monthly Ice Best Buys Now are designed to highlight our teamâs three favourite, most timely Buys from our growing list of income-focused Ice recommendations, to help Fools build out their portfolios. âBest Buys Nowâ Pick #1: GSK (LSE: GSK) In ...
motleyfooluklse:gsk
Financial services and pharmaceuticals are two very different industries. I think one stock from each of these could prove to be excellent income stocks. The two picks I’m referring to are abrdn (LSE: ABDN) and GSK (LSE: GSK). Here’s why I reckon investors should consider buying some shares. abrdn Since ...
motleyfooluklse:gsklse:abdn
For a while, I’ve wanted to invest in GSK (LSE: GSK) and treat it as an income stock in my portfolio. However, the waters have been muddy, and the business has yet to prove itself to me. Back in July 2022, the company completed the demerger of its consumer healthcare business, which became Haleon. The ...
motleyfooluklse:gsk
The GSK (LSE: GSK) share price really makes me scratch my head. Or, rather, its valuation does. Investors have pushed AstraZeneca shares up 90% in the past five years. GSK, though, is up just 3% in the same time, well behind the FTSE 100‘s 9%. Covid effect It has to be the Covid effect. After all, only ...
motleyfooluklse:gsk
Premium content from Motley Fool Share Advisor UK Our monthly Ice Best Buys Now are designed to highlight our teamâs three favourite, most timely Buys from our growing list of income-focused Ice recommendations, to help Fools build out their portfolios. âBest Buys Nowâ Pick #1: GSK (LSE: GSK) On ...
motleyfooluklse:gsk
GSK (LSE:GSK) shares are up 18.9% over six months. And much of that growth has come in the past month. So if I had invested £1,000 in GSK stock six months, today I’d have £1,189, plus about £10 in the form of dividends — paid on 11 January. That’s clearly a pretty successful investment. However, is this ...
motleyfooluklse:gsk
Two dividend stocks I think would be ideal for helping me build a second income stream are GSK (LSE: GSK) and Anglo American (LSE: AAL). Here’s why! Essential healthcare GSK is one of the biggest pharmaceutical businesses in the world with a mammoth footprint and a plethora of well-known products used ...
motleyfooluklse:gsklse:aal
I’m always keen to add a top value stock or two to add to my portfolio. I was therefore interested to see Derren Nathan, head of equity research at Hargreaves Lansdown, highlight two “unloved companies” on the FTSE 100. He said “weak investor sentiment does not reflect the longer-term prospects”. That’s ...
motleyfooluklse:gsklse:bats
The healthcare sector can be a great place to look for income because medicine is considered non-cyclical due to its essential nature. Here are three dividend stocks with decent yields that investors might want to consider buying in 2024. Pfizer First up is biopharmaceutical giant Pfizer (NYSE: PFE). ...
motleyfoolukusx:pfelse:gskusx:mdt
Getting paid for doing nothing beyond owning a company’s shares is, in my view, the greatest kind of passive income. This only gets better if I buy my stake at a bargain price. This way, I might get a nice bit of profit on top of those tasty dividends if and when sentiment improves. Here are three tried ...
motleyfooluklse:gsklse:ulvrlse:dge
I’ve been hunting around for exciting opportunities to add to my Stocks and Shares ISA in the year ahead. A couple have really caught my eye. They were highlighted by AJ Bell investment director Russ Mould. He reckons there’s plenty of value to be found on the FTSE All-Share today, a view I share. While ...
motleyfooluklse:gsklse:ashm
News from FTSE shares tend to dry up in December. But I think a few of my favourites might just get a boost from January updates. It poses a tricky question. If we’re bullish about a stock, should we buy before the news, or wait and see if it’s what we hoped? There’s an old saying that we should “buy ...
motleyfooluklse:gsklse:psnlse:mks